Adoram Therapeutics, a Geneva-based biotech company spun off from the University of Geneva, specializing in allosteric modulators for cancer immunotherapy and inflammatory conditions, is excited to announce that it has secured a pre-seed investment to accelerate its groundbreaking research.

总部位于日内瓦的生物技术公司Adoram Therapeutics是从日内瓦大学分拆出来的，专注于癌症免疫治疗和炎症疾病的变构调节剂。该公司兴奋地宣布，已获得一笔预种子轮投资，以加速其突破性研究。

The pre-seed funding round was led by private business angels, Ipalmetrix, and

预种子轮融资由私人商业天使、Ipalmetrix领投，

FONGIT

FONGIT

- the Geneva incubator. This investment will enable

- 日内瓦孵化器。这项投资将使

Adoram Therapeutics

阿多拉姆治疗学

to accelerate the development of its novel small molecule drugs designed to enhance the immune response in cancer patients and address multiple inflammation or autoimmune-related conditions.

加速开发其新型小分子药物，旨在增强癌症患者的免疫反应，并解决多种炎症或自身免疫相关疾病。

'We are thrilled to receive this support as it significantly aids our efforts to bring innovative therapies to the clinic,' said Dr. David PEJOSKI, co-CEO and co-founder of Adoram Therapeutics. He added, “Contributions and endorsement from private investors and FONGIT, empowers Adoram Therapeutics to advance to the next stage of growth and strengthens our position in the Swiss Biotech community.

“我们很高兴获得这一支持，因为它极大地帮助了我们将创新疗法推向临床的努力，”Adoram Therapeutics的联合首席执行官兼联合创始人David PEJOSKI博士说道。他补充道：“来自私人投资者和FONGIT的贡献与认可，使Adoram Therapeutics能够迈向下一个成长阶段，并巩固了我们在瑞士生物技术领域的地位。”

We wholeheartedly thank our investors for their trust in our vision to develop next-generation small molecule therapies for patients with unmet medical needs.”.

我们衷心感谢投资者对我们为未满足医疗需求的患者开发下一代小分子疗法的愿景的信任。"

'This funding is a testament to the potential of our approach and the dedication of our team. It will be instrumental in getting our immune-oncology program closer to the clinic and consolidating the proof-of-concept studies of our anti-inflammatory asset. It will also enable the use of our differentiated platform to expand the pipeline in collaboration with co-development partners.

“这笔资金证明了我们方法的潜力和团队的奉献精神。它将有助于我们的免疫肿瘤学项目更接近临床，并巩固我们抗炎资产的概念验证研究。它还将使我们能够利用差异化的平台，与共同开发合作伙伴合作扩展产品线。”

We aim to continue discovering small molecule allosteric modulators for validated GPCR targets for patients in need of efficacious therapies' said Dr Hesham HAMED, co-CEO/CSO of Adoram Therapeutics..

阿多拉姆治疗公司联合首席执行官/首席科学官赫沙姆·哈梅德博士表示：“我们的目标是继续为经过验证的GPCR靶点发现小分子变构调节剂，以帮助那些需要有效疗法的患者。”

Generous grants from the Swiss national innovation agency, Innosuisse, and the Geneva tech transfer office, UNITEC, allowed the conception of these ideas and the delivery of proof-ofconcept studies in immuno-oncology and inflammation. The work done in the Pharmaceutical Biochemistry lab at University of Geneva led by Prof.

来自瑞士国家创新机构Innosuisse和日内瓦技术转让办公室UNITEC的慷慨资助，使得这些想法得以构思，并在免疫肿瘤学和炎症领域完成了概念验证研究。这项工作是在日内瓦大学由教授领导的药物生物化学实验室完成的。

Scapozza, laid the groundwork for the current advancements..

斯卡波扎为当前的进步奠定了基础。

With this investment, Adoram Therapeutics aims to continue its mission of developing safer and more effective immunotherapies for patients with solid tumors and innovative treatments for inflammation-related diseases.

通过这笔投资，Adoram Therapeutics 旨在继续其为实体瘤患者开发更安全、更有效的免疫疗法以及为炎症相关疾病提供创新治疗的使命。

(PR)

（公共关系）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或者

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送